{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:16:05Z","timestamp":1787015765152,"version":"build-2736575974"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2955,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021663","name":"Toledo Community Foundation","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100021663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid dysfunction is associated with the use of tyrosine kinase inhibitors (TKI) in people.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>To determine whether dysfunction in the hypothalamic-pituitary-thyroid axis occurs in dogs receiving the TKI, toceranib phosphate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Forty-three client-owned dogs with cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, observational study. Concentrations of total thyroxine (TT4), free thyroxine (FT4), total triiodothyronine (TT3), and thyroid-stimulating hormone (TSH) were evaluated on day 0, 30, and 90. Dogs also were evaluated for the presence of thyroglobulin autoantibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The proportion of dogs with low TT4, low FT4, low TT3, high TSH, or primary hypothyroidism (increased TSH and decreased TT4, FT4 or both) did not change over 90 days. Hormone concentrations remained within laboratory reference intervals, but FT4 (P = 0.0032) and TSH (P &amp;lt; 0.0001) changed over time. Mean FT4 was 1.22 ng\/dL (95% confidence interval [CI], 1.10\u20131.34) on day 0 and 1.00 ng\/dL (95% CI, 0.86\u20131.16) on day 90. Mean TSH was 0.17 ng\/mL (95% CI, 0.13\u20130.23) on day 0 and 0.34 ng\/mL (95% CI, 0.24\u20130.48) on day 90. Furthermore, TT4\/TT3 ratio also changed over time (P = 0.0086). Mean TT4\/TT3 ratio was 2.57 (95% CI, 2.26\u20132.88) on day 0 and 2.02 on day 90 (95% CI, 1.61\u20132.44). Thyroglobulin autoantibodies were not detected in any dog.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Toceranib phosphate can disrupt the hypothalamic-pituitary-thyroid axis in dogs. Periodic evaluation of TT4, FT4, TT3, and TSH should be carried out in dogs receiving long-term treatment with this medication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.14882","type":"journal-article","created":{"date-parts":[[2017,11,30]],"date-time":"2017-11-30T01:12:35Z","timestamp":1512004355000},"page":"377-383","source":"Crossref","is-referenced-by-count":12,"title":["Effects of Toceranib Phosphate on the Hypothalamic-Pituitary-Thyroid Axis in Tumor-Bearing Dogs"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9935-2118","authenticated-orcid":false,"given":"K.R.","family":"Hume","sequence":"first","affiliation":[{"name":"Cornell University College of Veterinary Medicine Department of Clinical Sciences, , Ithaca, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.L.","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Cornell University College of Veterinary Medicine , Ithaca, NY"},{"name":"Summit Veterinary Referral Center , Tacoma, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.R.","family":"Cawley","sequence":"additional","affiliation":[{"name":"Cornell University College of Veterinary Medicine , Ithaca, NY"},{"name":"Colorado State University College of Veterinary Medicine and Biosciences Department of Clinical Sciences, , Fort Collins, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.","family":"Balkman","sequence":"additional","affiliation":[{"name":"Cornell University College of Veterinary Medicine Department of Clinical Sciences, , Ithaca, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,1]]},"reference":[{"key":"2026020303252479100_jvim14882-bib-0001","first-page":"2755","article-title":"Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies","volume":"9","author":"London","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2026020303252479100_jvim14882-bib-0002","article-title":"Palladia [package insert]","year":"2015"},{"key":"2026020303252479100_jvim14882-bib-0003","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1476-5829.2011.00275.x","article-title":"Preliminary evidence for biologic activity of toceranib phosphate (Palladia((R))) in solid tumours","volume":"10","author":"London","year":"2012","journal-title":"Vet Comp Oncol"},{"key":"2026020303252479100_jvim14882-bib-0004","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.critrevonc.2014.01.002","article-title":"Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group","volume":"91","author":"Sodergren","year":"2014","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026020303252479100_jvim14882-bib-0005","doi-asserted-by":"crossref","first-page":"R233","DOI":"10.1530\/ERC-13-0201","article-title":"Thyroid dysfunction and tyrosine kinase inhibitors in renal cell carcinoma","volume":"20","author":"Bianchi","year":"2013","journal-title":"Endocr Relat Cancer"},{"key":"2026020303252479100_jvim14882-bib-0006","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/ki.2011.288","article-title":"Proteinuria and hypertension with tyrosine kinase inhibitors","volume":"80","author":"Kandula","year":"2011","journal-title":"Kidney Int"},{"key":"2026020303252479100_jvim14882-bib-0007","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision","volume":"15","author":"London","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026020303252479100_jvim14882-bib-0008","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/1746-6148-9-190","article-title":"Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose","volume":"9","author":"Bernabe","year":"2013","journal-title":"BMC Vet Res"},{"key":"2026020303252479100_jvim14882-bib-0009","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/jvim.13951","article-title":"Effects of toceranib phosphate on systolic blood pressure and proteinuria in dogs","volume":"30","author":"Tjostheim","year":"2016","journal-title":"J Vet Intern Med"},{"key":"2026020303252479100_jvim14882-bib-0010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11523-011-0197-2","article-title":"Tyrosine kinase inhibitor-induced hypothyroidism: Incidence, etiology, and management","volume":"6","author":"Brown","year":"2011","journal-title":"Target Oncol"},{"key":"2026020303252479100_jvim14882-bib-0011","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-145-9-200611070-00008","article-title":"Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors","volume":"145","author":"Desai","year":"2006","journal-title":"Ann Intern Med"},{"key":"2026020303252479100_jvim14882-bib-0012","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: A prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"2026020303252479100_jvim14882-bib-0013","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.clpt.2005.06.010","article-title":"Imatinib induces hypothyroidism in patients receiving levothyroxine","volume":"78","author":"de Groot","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"2026020303252479100_jvim14882-bib-0014","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/jc.2011-1172","article-title":"Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression","volume":"96","author":"Kappers","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026020303252479100_jvim14882-bib-0015","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2026020303252479100_jvim14882-bib-0016","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/thy.2006.0308","article-title":"Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity","volume":"17","author":"Wong","year":"2007","journal-title":"Thyroid"},{"key":"2026020303252479100_jvim14882-bib-0017","doi-asserted-by":"crossref","first-page":"E100","DOI":"10.1210\/jc.2011-1837","article-title":"Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport","volume":"97","author":"Braun","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026020303252479100_jvim14882-bib-0018","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/thy.2015.0170","article-title":"Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: Is thyroid autoimmunity involved?","volume":"25","author":"Pani","year":"2015","journal-title":"Thyroid"},{"key":"2026020303252479100_jvim14882-bib-0019","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"key":"2026020303252479100_jvim14882-bib-0020","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1089\/thy.2007.0336","article-title":"Effect of sunitinib on growth and function of FRTL-5 thyroid cells","volume":"18","author":"Salem","year":"2008","journal-title":"Thyroid"},{"key":"2026020303252479100_jvim14882-bib-0021","first-page":"176","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): A Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp","volume":"13","author":"Nguyen","year":"2015","journal-title":"Oncol"},{"key":"2026020303252479100_jvim14882-bib-0022","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/jvim.12573","article-title":"Free thyroxine concentrations by equilibrium dialysis and chemiluminescent immunoassays in 13 hypothyroid dogs positive for thyroglobulin antibody","volume":"29","author":"Randolph","year":"2015","journal-title":"J Vet Intern Med"},{"key":"2026020303252479100_jvim14882-bib-0023","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jama.1990.03440110095035","article-title":"American Thyroid Association guidelines for use of laboratory tests in thyroid disorders","volume":"263","author":"Surks","year":"1990","journal-title":"JAMA"},{"key":"2026020303252479100_jvim14882-bib-0024","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cvsm.2007.05.015","article-title":"Testing for hypothyroidism in dogs","volume":"37","author":"Ferguson","year":"2007","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2026020303252479100_jvim14882-bib-0025","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jama.291.2.228","article-title":"Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management","volume":"291","author":"Surks","year":"2004","journal-title":"JAMA"},{"key":"2026020303252479100_jvim14882-bib-0026","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1210\/edrv.23.1.0455","article-title":"Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases","volume":"23","author":"Bianco","year":"2002","journal-title":"Endocr Rev"},{"key":"2026020303252479100_jvim14882-bib-0027","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/11318860-000000000-00000","article-title":"Sunitinib: A multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies","volume":"23","author":"Papaetis","year":"2009","journal-title":"BioDrugs"},{"key":"2026020303252479100_jvim14882-bib-0028","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2026020303252479100_jvim14882-bib-0029","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2460\/javma.2001.219.765","article-title":"Serum total thyroxine, total triiodothyronine, free thyroxine, and thyrotropin concentrations in dogs with nonthyroidal disease","volume":"219","author":"Kantrowitz","year":"2001","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303252479100_jvim14882-bib-0030","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cvsm.2012.04.012","article-title":"Thyroid disorders in the geriatric veterinary patient","volume":"42","author":"Scott-Moncrieff","year":"2012","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2026020303252479100_jvim14882-bib-0031","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1939-1676.2003.tb02467.x","article-title":"Influence of drugs on thyroid function in dogs","volume":"17","author":"Daminet","year":"2003","journal-title":"J Vet Intern Med"},{"key":"2026020303252479100_jvim14882-bib-0032","first-page":"411","article-title":"Short-term influence of prednisone and phenobarbital on thyroid function in euthyroid dogs","volume":"40","author":"Daminet","year":"1999","journal-title":"Can Vet J"},{"key":"2026020303252479100_jvim14882-bib-0033","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1210\/jcem-43-2-338","article-title":"The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin","volume":"43","author":"Re","year":"1976","journal-title":"J Clin Endocrinol Metab"},{"key":"2026020303252479100_jvim14882-bib-0034","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF03348767","article-title":"Acute and chronic effects of high glucocorticoid levels on hypothalamic-pituitary-thyroid axis in man","volume":"15","author":"Rubello","year":"1992","journal-title":"J Endocrinol Invest"},{"key":"2026020303252479100_jvim14882-bib-0035","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2460\/ajvr.1991.52.03.416","article-title":"Effect of oral administration of prednisolone on thyroid function in dogs","volume":"52","author":"Torres","year":"1991","journal-title":"Am J Vet Res"},{"key":"2026020303252479100_jvim14882-bib-0036","doi-asserted-by":"crossref","first-page":"130","DOI":"10.2460\/ajvr.1993.54.01.130","article-title":"Effects of oral administration of anti-inflammatory doses of prednisone on thyroid hormone response to thyrotropin-releasing hormone and thyrotropin in clinically normal dogs","volume":"54","author":"Moore","year":"1993","journal-title":"Am J Vet Res"},{"key":"2026020303252479100_jvim14882-bib-0037","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF00315221","article-title":"The effects of drugs on tests of thyroid function","volume":"40","author":"Davies","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"2026020303252479100_jvim14882-bib-0038","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/bmj.281.6245.911","article-title":"Prospective study of effect of fenclofenac on thyroid function tests","volume":"281","author":"Taylor","year":"1980","journal-title":"Br Med J"},{"key":"2026020303252479100_jvim14882-bib-0039","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0002-9343(94)90148-1","article-title":"Effects of commonly prescribed nonsteroidal anti-inflammatory drugs on thyroid hormone measurements","volume":"96","author":"Bishnoi","year":"1994","journal-title":"Am J Med"},{"key":"2026020303252479100_jvim14882-bib-0040","first-page":"474","article-title":"Effects of oral administration of meloxicam, carprofen, and a nutraceutical on thyroid function in dogs with osteoarthritis","volume":"44","author":"Sauv\u00e9","year":"2003","journal-title":"Can Vet J"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.14882","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/32\/1\/377\/66672780\/jvim14882.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/32\/1\/377\/66672780\/jvim14882.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:25:37Z","timestamp":1770107137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/32\/1\/377\/8449746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.14882","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2018,1,1]]}}}